Fundraising Fox
InjectSense
Emeryville, US · Founded 2014 · Delaware corporation
Find your way into InjectSense
Sign up to see every warm intro you have to InjectSense
- Paths you didn't know you had: your email and LinkedIn already hold routes to the InjectSense team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Injectsense develops implant-based digital health systems that use semiconductor technology to provide medical staff with continuous long-term monitoring data for therapy management, with an ophthalmology focus including eye-pressure markers. The company combines ultra-low power IC design, telemetry, and miniaturization with medical device and software expertise.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$13.9M disclosed across 2 rounds · 2017–2019
▶$4.1MraisedApr 2019 · 23 investors · OtherRule 506(b)
▶$4.1MraisedApr 2019 · 23 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Enrique MalaretExecutive Officer, Director
- Ariel CaoExecutive Officer, Director
- Zack ScottDirector
- Offering amount
- $8.4M
- Amount sold
- $4.1M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$9.8MraisedOct 2017 · 42 investors · OtherRule 506(b)
▶$9.8MraisedOct 2017 · 42 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Enrique MalaretExecutive Officer, Director
- Ariel CaoExecutive Officer, Director
- Offering amount
- $9.8M
- Amount sold
- $9.8M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
InfusenseInfuSense develops an electrochemical sensing technology platform that detects analytes at sub-therapeutic levels, delivering sample analysis results within minutes. The portable device is designed to bring laboratory-scale testing capabilities into a handheld form factor.
Senseonics HoldingsSenseonics develops and commercializes Eversense, an implantable continuous glucose monitoring system designed to measure blood sugar levels for up to one year in people with diabetes, offering an alternative to conventional glucose monitors that require more frequent sensor replacement. The company sells its system directly and through distribution partners in the United States and Europe.
CranioSenseCranioSense develops IPASS, a non-invasive medical device that measures intracranial pressure using a forehead patch and handheld device, eliminating the need for invasive skull drilling in traumatic brain injury assessment.
ClearsenseClearsense operates the 1Clearsense Platform, a healthcare data lakehouse that unifies and manages disparate data for health systems and presents it in simplified, actionable views. The company targets health systems to reduce costs, improve operational efficiency, accelerate research and impact care outcomes.
OphthalmologytimesOphthalmology Times is a medical news publication covering clinical research, drug approvals, and treatment developments in eye care for ophthalmologists and other eye care professionals. It publishes articles, videos, podcasts, a digital edition, and continuing medical education content.
NirsenseNIRSense builds ruggedized, wireless hospital-quality patient monitors that measure tissue oxygen kinetics and other physiological data, including arterial (SpO2) and tissue (StO2) oxygenation, to help clinicians diagnose and treat critical conditions such as cardiogenic shock. Its devices are designed for use in uncontrolled environments including emergency and intensive care settings and military front lines.
SisenseSisense provides embedded analytics software that enables teams to integrate data visualization and insights into business applications. The platform serves product development teams and enterprises seeking to build data-driven features into their software products.
Companies working in the same space as InjectSense.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.6M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does InjectSense do?
- Injectsense develops implant-based digital health systems that use semiconductor technology to provide medical staff with continuous long-term monitoring data for therapy management, with an ophthalmology focus including eye-pressure markers. The company combines ultra-low power IC design, telemetry, and miniaturization with medical device and software expertise.
- How much funding has InjectSense raised?
- InjectSense has disclosed $13.9M raised across 2 rounds.
- Where is InjectSense headquartered?
- InjectSense is headquartered in Emeryville, US.